http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2403041-C2

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a05b4130cc8bb18a1fae752cb6cf30fc
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/B82B1-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-42
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-14
filingDate 2008-12-18-04:00^^<http://www.w3.org/2001/XMLSchema#date>
grantDate 2010-11-10-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bcdb87bcb09d28fecfee0fe600797252
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6c113459addb9041a1c72c9ecdf2af04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9bb318606a08842d67f344d0cdd96fa1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_49c1cc3ee9f4bf321f22fdfb1b98d7d4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fac17a23e6b06774e5331f75a51bc72a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ec6bf71fc957dd0c86c15585308fe1e1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8ebe1c653b1073eae49d5227eddf9bac
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_305c5f6b007f35e2abbb223114492ed3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f33d91c80f141dd73e24442b8d3b9353
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8327277b923eb0dd83d8e577d32cf5e7
publicationDate 2010-11-10-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber RU-2403041-C2
titleOfInvention D-cycloserin-based medication of plolonged action with dosed release in target organs for treatment of resistant forms of tuberculosis
abstract FIELD: medicine, pharmaceutics. n SUBSTANCE: invention relates to field of pharmacology and medicine, namely to new generation of antimicrobial D-cycloserin-based medications of regulated action. Described is medication of anti-microbial action with prolonged release into target organs, characterised in that it represents stable nanoparticles and includes D-cycloserin, PLGA 50/50, D-mannit and polyvinyl alcohol, with the following component ratio, wt %: D-cycloserin from 1 to 15; PLGA 50/50 from 20 to 40; D-mannit from 5 to 40; polyvinyl alcohol from 5 to 15. Described medication has considerably lower neurotoxicity and is able to produce bactericidal effect with respect to Mycobacterium tuberculosis, without producing toxic effect and possessing high therapeutic efficiency. n EFFECT: application of elaborated medication allows to achieve highly selective dosed release of active substance into target organs-cells (macrophages). n 5 ex, 1 tbl
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2589823-C2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2606839-C1
priorityDate 2008-12-18-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419559037
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419574725
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID151263
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID136460
http://rdf.ncbi.nlm.nih.gov/pubchem/taxonomy/TAXID1789
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID415853316
http://rdf.ncbi.nlm.nih.gov/pubchem/anatomy/ANATOMYID1773
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6234
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID71080
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419534805
http://rdf.ncbi.nlm.nih.gov/pubchem/taxonomy/TAXID1773
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419536206
http://rdf.ncbi.nlm.nih.gov/pubchem/anatomy/ANATOMYID1789
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6251

Total number of triples: 39.